Can Trazodone Cause Tremors and Shaking?

Trazodone can cause tremors and shaking, though it does so uncommonly compared to its more frequent side effects like drowsiness and dizziness. The tremors fall under a broader category of movement problems that have been documented in case reports and pharmacovigilance databases, ranging from mild resting tremors to more complex involuntary movements. The good news is that these effects appear to be reversible in most reported cases once the drug is stopped, but they deserve attention because they can be mistaken for the onset of a neurological disease like Parkinson’s.

What Kinds of Tremors and Movement Problems Have Been Reported

The movement issues linked to trazodone are not limited to a single type of tremor. Published case reports describe several distinct patterns. One report detailed a 55-year-old woman who developed resting tremor, postural tremor, and myoclonus after starting trazodone, illustrating how multiple movement disorder types can show up in the same person.¹ Another case described a middle-aged man who developed mild resting tremors along with bradykinesia and rigidity in both upper limbs, a presentation that closely mimicked Parkinson’s disease.²

Beyond tremors specifically, trazodone has been associated with other involuntary movements. A pharmacovigilance analysis of the FDA’s adverse event reporting system identified reports of dyskinesia, including orofacial dyskinesia (involuntary movements of the mouth and face) and restless legs syndrome in trazodone users.³ There is even a reported case of tardive dystonia, where a woman developed sustained involuntary muscle contractions along with an unusual tactile sensory syndrome after taking just 50 mg per day for 19 months.⁴ The word “tardive” here matters: it means the symptoms emerged after prolonged use rather than right away, and tardive movement disorders can sometimes persist even after the drug is stopped.

So the short version is that trazodone-related movement problems can look quite different from person to person. Some people get a fine tremor at rest. Others develop stiffness and slowed movement. Still others experience jerky involuntary motions in their face or limbs. The common thread is that all of these fall under the umbrella of “extrapyramidal” effects, meaning they involve the brain circuits that normally keep your movements smooth and coordinated.

Why a Sleep and Depression Drug Affects Movement

Trazodone is primarily known as a serotonin modulator. It blocks certain serotonin receptors and inhibits serotonin reuptake, which is how it helps with depression, anxiety, and insomnia. But the brain’s neurotransmitter systems do not operate in neat silos. Trazodone also has some antagonistic effect on dopamine receptors, and dopamine is the neurotransmitter most closely tied to smooth, voluntary movement.³ When dopamine signaling in certain brain regions gets dampened, the result can be the same stiffness, tremor, and slowness seen in Parkinson’s disease, which is itself caused by dopamine-producing neurons dying off.

One case report specifically noted that trazodone can inhibit dopaminergic neurotransmission in the midbrain, leading to the emergence of extrapyramidal effects.⁵ This is the same brain region affected in Parkinson’s disease, which is why trazodone-induced movement symptoms can look so similar to actual Parkinson’s that clinicians may initially confuse the two.

There is a second pathway that may contribute. When your body breaks down trazodone, one of the resulting metabolites is called mCPP (meta-chlorophenylpiperazine). This metabolite activates a specific type of serotonin receptor and has been shown in animal studies to produce abnormal oral and facial movements.⁶ This may help explain why some people on trazodone develop involuntary movements concentrated around the mouth and jaw rather than the classic limb tremor. The dual mechanism, involving both dopamine disruption and an active metabolite with its own movement-affecting properties, makes the picture more complex than a simple dose-response story.

How Quickly Can Tremors Appear

The timeline varies considerably. In some cases, movement problems develop rapidly. One elderly man who was given trazodone as a sleep aid developed full-blown parkinsonism, with rigidity and slowed movements, within a short period of starting the drug. Crucially, the authors described this as a “rapid development,” emphasizing that it caught his care team off guard because the dose was modest and he had no history of movement disorders.⁵

On the other end of the spectrum, the case of tardive dystonia described earlier appeared only after 19 months of daily use at a low 50 mg dose.⁴ Tardive syndromes are notoriously sneaky: they build gradually and sometimes are not recognized until they are well established. This range, from days to over a year, means there is no single window you can watch and then relax. If you are on trazodone and new involuntary movements appear at any point during treatment, the drug should be considered a possible cause.

Does the Dose Matter

You might assume that tremors would only appear at high doses, but the evidence suggests otherwise. The tardive dystonia case involved just 50 mg per day, which is at the low end of the prescribing range and is, in fact, the most common dose used for insomnia.⁴ The authors of that report stressed that even at a low dose, trazodone may pose a risk of tardive syndromes. This is a meaningful finding because trazodone at 25 to 100 mg is widely prescribed off-label for sleep, often with the assumption that these low doses carry minimal risk of serious neurological side effects.

That said, the pharmacological reality is that higher doses produce more dopamine receptor blockade and generate more of the mCPP metabolite, so it would be reasonable to expect that higher doses carry more risk. But the case literature makes clear that “low dose” is not a guarantee of safety when it comes to movement effects. Individual differences in how quickly a person metabolizes trazodone, their age, and whether they are taking other medications that affect the same neurotransmitter systems all influence the actual exposure their brain experiences.

Who Is More Vulnerable

Older adults appear to be disproportionately represented in the case literature on trazodone-induced movement disorders. The parkinsonian case from Clinical Neuropharmacology involved an elderly man, and trazodone is heavily prescribed in this age group for sleep disturbances, including among people with dementia.⁵ Aging brains have fewer dopamine-producing neurons to begin with, so a drug that further dampens dopamine signaling is pushing an already-vulnerable system closer to the threshold where movement problems appear. This is one reason why drug-induced parkinsonism in general is far more common in the elderly than in younger adults.

People taking multiple medications that affect serotonin or dopamine are also at increased risk. Trazodone is often added to an existing regimen that may include SSRIs, antipsychotics, or other drugs with their own movement-related side effect profiles. Each additional drug nudging the same neurotransmitter pathways raises the cumulative risk. And anyone who already has a subtle, undiagnosed movement disorder or early-stage neurodegenerative disease may have their symptoms unmasked or worsened by trazodone.

Trazodone-Induced Tremors Versus Actual Parkinson’s Disease

This is where things get clinically tricky and personally alarming for patients. When someone on trazodone develops resting tremor, stiffness, and slowed movement, the presentation can be nearly identical to early Parkinson’s disease. In the case of the middle-aged man who developed bilateral upper-limb tremors, rigidity, and bradykinesia, the initial clinical picture was that of a person developing Parkinson’s.² What distinguished it was the temporal relationship: the symptoms appeared after trazodone was started and resolved after it was stopped.

A few clinical clues can help tell the two apart. Drug-induced parkinsonism tends to affect both sides of the body relatively symmetrically, whereas idiopathic Parkinson’s typically begins on one side. Drug-induced symptoms often improve within weeks to months of stopping the medication, while true Parkinson’s is progressive and does not remit. But these distinctions are not always clean-cut, and the only reliable test in many cases is a supervised trial of drug withdrawal, which takes time and monitoring. For anyone who develops new tremors or movement changes while taking trazodone, bringing this up with a prescriber promptly is important: the difference between a drug side effect and a neurodegenerative disease is enormous, and a correct diagnosis depends on considering the medication history.

What Happens When Trazodone Is Stopped

The encouraging finding across published cases is that trazodone-induced movement problems appear to be largely reversible. The authors of the parkinsonism case in the elderly man specifically noted that the effect was “seemingly fully reversible” once trazodone was discontinued.⁵ Other case reports describe similar resolution of symptoms after withdrawal of the drug.

There is an important exception, however. Tardive syndromes, the ones that develop after prolonged use, are less predictable. While many do resolve, tardive movement disorders can sometimes persist for months or even permanently after the offending drug is removed. The 19-month tardive dystonia case is a reminder that the longer a movement disorder has been present before the drug is stopped, the less certain full recovery becomes.⁴ This underscores the value of recognizing movement side effects early rather than waiting to see if they worsen.

How Trazodone-Related Tremors Are Treated

If tremors are clearly linked to trazodone, the first and most straightforward approach is to stop or reduce the drug, or switch to an alternative that does not carry the same movement risk. A systematic review of medication-induced tremor treatment recommended starting with sequential withdrawal, reduction, or substitution of the likely causative agent and waiting three to six months to assess improvement.⁷

When stopping the medication is not feasible, perhaps because trazodone is the only drug that adequately controls a patient’s insomnia or depression, or when the tremor persists even after discontinuation, additional treatments can be considered. The same review outlined a stepwise approach:

Propranolol: A beta-blocker commonly used for essential tremor, dosed up to 100 mg daily as a first-line option.
Tetrabenazine: A drug that depletes dopamine and serotonin from nerve terminals, considered as a second option at doses up to 100 mg per day, though genetic testing for how a patient metabolizes the drug is recommended before going above 50 mg daily.
Metoprolol: Another beta-blocker, tried if propranolol is not tolerated or effective.
Deep brain stimulation: Reserved for rare, severe, disabling cases where no medical treatment has worked, drawing on the extensive experience with DBS for other types of tremor.

The progression from simple drug withdrawal to surgical intervention reflects how unusual it is for trazodone-related tremor to require aggressive treatment. Most cases resolve with medication changes alone. But having a formal treatment algorithm is useful for the rare patient whose tremor lingers.

Why Side Effects Like Tremors Often Go Unreported

One reason trazodone-related tremors may be underrecognized is that clinicians tend to underestimate the prevalence of antidepressant side effects in general. Research on antidepressant adherence has found that roughly one in four patients stops taking their antidepressant because of side effects that are difficult to tolerate, and many others continue taking the medication while experiencing reduced quality of life from troublesome effects.⁸ A fine tremor in the hands might not be the kind of dramatic symptom that prompts an urgent call to the doctor, especially if the patient assumes it is due to anxiety, caffeine, or aging. By the time it becomes bothersome enough to mention, weeks or months may have passed, making it harder to connect the symptom to the drug.

The problem is compounded by trazodone’s reputation as a relatively gentle medication. Because it is not an antipsychotic, many prescribers and patients do not think of it as a drug that can cause movement disorders. The published case reports consistently note that this adverse effect is underappreciated and that greater awareness is needed across all healthcare settings, not just neurology clinics.⁵

Sleep-Related Jerks and Trazodone

There is a separate phenomenon worth distinguishing from the movement disorders discussed above: hypnic jerks, those sudden whole-body twitches that sometimes happen as you are falling asleep. These are extremely common in the general population and are usually harmless. One clinical case described a patient who took trazodone 50 mg every other night to aid sleep and reported having less frequent hypnic jerks while on it, though the same patient also had severe obstructive sleep apnea with significant sleep fragmentation and frequent axial myoclonic contractions.⁹ The relationship between trazodone and sleep-related jerks is murky, and any changes in nighttime twitching while on the drug could reflect improved or disrupted sleep architecture rather than a direct drug effect on movement circuits.

If you are experiencing new or worsened body jerks specifically around the transition to sleep while taking trazodone, it is worth mentioning to your doctor, but these are mechanistically distinct from the dopamine-related tremors and rigidity discussed earlier. The dopamine pathway effects produce symptoms that occur during waking hours and during voluntary movement or rest, not only at the sleep-wake boundary.

How Trazodone’s Movement Risks Compare to Other Antidepressants

Virtually all antidepressants have been linked to movement disorders in at least some case reports or pharmacovigilance analyses. SSRIs like fluoxetine, sertraline, and paroxetine are probably the most commonly reported culprits, partly because they are prescribed far more frequently. Among the serotonin-modulating drugs, trazodone’s movement risk appears to be lower than that of typical antipsychotics, which are well known for causing extrapyramidal symptoms, but higher than many prescribers assume for a drug in its class. The FDA adverse event reporting system has flagged dyskinesia as a recognized signal for trazodone, lending epidemiological weight to what had previously been only isolated case reports.³

What makes trazodone’s risk profile distinctive is the combination of its dual mechanism, direct dopamine receptor effects plus the mCPP metabolite, paired with its enormous off-label use for insomnia. Millions of people take low-dose trazodone nightly, many of them older adults, many on other medications that also influence dopamine or serotonin. Even if the absolute risk of movement disorders per individual is small, the sheer number of people exposed means a meaningful total number will be affected. And because trazodone is so often prescribed casually for sleep, the movement-related risks may not be discussed during prescribing the way they would be for an antipsychotic.

1
PubMed Central. Trazodone-Associated Extrapyramidal Syndrome: A Case Report and Review of Literature
2
PubMed Central. Trazodone-induced parkinsonism in a middle-aged male: A case report
3
Nature Publishing Group. A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
4
ScienceDirect (Elsevier). Tardive dystonia and tardive sensory syndrome related to trazodone: A case report
5
Clinical Neuropharmacology. Trazodone and Parkinsonism: The Link Strengthens
6
PubMed Central. Putative Mechanism of Action of Trazodone-Related Oromandibular Dyskinesia
7
PubMed Central. Medical and Surgical Treatment for Medication‐Induced Tremor: Case Report and Systematic Review
8
Dialogues in Clinical Neuroscience. Toward achieving optimal response: understanding and managing antidepressant side effects
9
Oxford Academic (SLEEP). Sleep-related hiccups: A case report of antidepressant associated hypnic jerks